AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioCardia Seeks Approval in Japan for Cell Therapy for Ischemic Heart Failure
ByAinvest
Monday, Sep 22, 2025 8:08 am ET1min read
BioCardia has had a positive preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on the CardiAMP Heart Failure Trial results. The agency requested additional details, including clarification on positioning of prespecified composite endpoints and clinical development status in the US. BioCardia is completing responses to their questions and anticipates formal clinical consultation near the end of the year. The company aims to enable access for patients with few therapeutic options who showed significant benefits in the CardiAMP HF study.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet